bookmark:
connotea
::
del.icio.us
::digg
::furl
::reddit
::yahoo::
redux [01.11.01]
Fool.Com Do Biotech Data Deals Mean Real Money?
"Biotech deals announced in the last few days highlight the hottest debate in the biotech world: If and how bioinformatics companies -- the likes of Gene Logic (Nasdaq: GLGC), Incyte Genomics (Nasdaq: INCY), and Celera Genomics (NYSE: CRA) -- can sustain long-term business success. Can they sell their information alone, obtain future milestone payments and royalties on drugs or diagnostics produced from their data, or must they become drug development companies themselves?"Fool.Com: Message Boards Re: Are royalties the key?
"Currently, big pharma subscribers are paying several million dollars per year, for several years, on a non-exclusive basis. Now if we assume you are correct in that unvalidated targets are worth MUCH less than validated targets (and I'm correct in assuming that first generation genomics targets are evn more likely to be "low margin") then, considering the time it will take to bring an unvalidated target to market, Celera is ripping these guys off (well, that's a little extreme). There's absolutely no guarantee any of this data will yield blockbuster drugs and yet they can charge tens of millions of dollars for it on a non-exclusive basis. Why does pharma buy it? Because several million a year is pocket change for a lot of these companies. Why risk missing out? Suckers.;-)
I realize I'm taking an extreme stance, but it's only to make a point: Celera is making a lot of money from their subscribers. The big question is can they continue to sign companies up at a rate sufficient to fund expansion of an internal drug discovery platform. Here we may have a problem. The subscription rate has been, for most of us, disappointing. Either Celera is going to have to start validating targets (or annotating or value-adding) to attract more customers, or they are going to have to enter into significant collaborations. I think they're going to do both."
GenomeWeb Celera Launches into Drug Target Sector
"Celera Genomics on Wednesday announced moves that signal the beginning of the company's foray into the drug target discovery sector.
"We are looking to identify new drug targets," Peter Chambre, Celera?s chief operating officer, said at a company presentation at the JP Morgan H&Q conference."
“Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.”
BIOINFORMATICS IN THE 21st CENTURY
biospace
/
genomeweb
/
bio-it world
/
scitechdaily
/
biomedcentral
/
the panda's thumb
/
bioinformatics.org
/
nodalpoint
/
flags and lollipops
/
on genetics
/
a bioinformatics blog
/
andrew dalke
/
the struggling grad student
/
in the pipeline
/
gene expression
/
free association
/
pharyngula
/
the personal genome
/
genetics and public health blog
/
the medical informatics weblog
/
linuxmednews
/
nanodot
/
complexity digest
/
eyeforpharma
/
nsu
/
nyt science
/
bbc scitech
/
newshub
/
biology news net
/
informatics review
/
stanford
/
bmj info in practice
/
bmj info in practice
/
look snazzy and support the site at the same time by buying some snowdeal schwag !
valid xhtml 1.0?
This site designed by
Eric C. Snowdeal III
.
© 2000-2005